M

Mid Atlantic Retina | Philadelphia/Wills Eye Hospital

Research site

(Unclaimed)

Location

840 Walnut Street, Suite 1020, Philadelphia, Pennsylvania, United States of America

Site insights

Top conditions

Top treatments

Ranibizumab

Lampalizumab

Aflibercept

timolol

Faricimab

Dorzolamide

Zimura

Brimonidine

Avacincaptad pegol

Timolol

Parent organization

This site is a part of Mid Atlantic Retina

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 50 total trials

Locations recently updated

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy (SIENNA)

This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atroph...

Enrolling

Age-related Macular Degeneration (AMD)

Geographic Atrophy (GA)

Drug: Placebo

Drug: Pozelimab

Extension Study for the Port Delivery System With Ranibizumab (Portal)

This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with ne...

Enrolling

Neovascular Age-Related Macular Degeneration

Drug: PDS Implant with Ranibizumab 100 mg/mL

ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study

The purpose of this study is to evaluate the long-term safety of GT005 in participants with Geographic Atrophy (GA) secondary to AMD who have been tr...

Invitation-only

Age Related Macular Degeneration (AMD)

Genetic: GT005

Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration (BURGUNDY)

This is a first in-human study to investigate the safety, tolerability and efficacy of zifibancimig administered through intravitreal (IVT) injection...

Active, not recruiting

Macular Degeneration

Drug: Ranibizumab

Drug: Zifibancimig